Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts

[1]  J. Winter,et al.  The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study , 2005, Annals of Hematology.

[2]  Y. Pommier.  DNA topoisomerase I and II in cancer chemotherapy: update and perspectives , 2004, Cancer Chemotherapy and Pharmacology.

[3]  A. Hagemeijer,et al.  Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. , 2001, Blood.

[4]  N. Niitsu,et al.  Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study , 2001, Annals of Hematology.

[5]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[6]  M. Lübbert,et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Benz,et al.  Low‐dose melphalan induces favourable responses in elderly patients with high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia , 2000, British journal of haematology.

[8]  T. Saotome,et al.  Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  E. Estey,et al.  Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Takimoto Ch,et al.  An overview of topoisomerase I-targeting agents. , 1998 .

[11]  H. Kantarjian,et al.  Topotecan in the treatment of hematologic malignancies. , 1998, Seminars in hematology.

[12]  S. Arbuck,et al.  An overview of topoisomerase I-targeting agents. , 1998, Seminars in hematology.

[13]  E. Wattel,et al.  Long‐term follow‐up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long‐term survivors and outcome of partial responders , 1997, British journal of haematology.

[14]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[15]  Marie-Cécile Michallet,et al.  Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle , 1996 .

[16]  H. Dombret,et al.  Timed sequential chemotherapy for advanced acute myeloid leukemia. , 1996, Hematology and cell therapy.

[17]  C. Chastang,et al.  Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle. , 1996, Blood.

[18]  P. Hérait,et al.  Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Y. Ohashi,et al.  Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy. , 1994, British Journal of Cancer.

[20]  M. Matsuoka,et al.  [Treatment of adult T-cell leukemia-lymphoma]. , 1994, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[21]  P. Hérait,et al.  Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. , 1994, Journal of the National Cancer Institute.

[22]  G. Weiss,et al.  Phase I and pharmacokinetic trial of weekly CPT-11. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Appelbaum,et al.  Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. , 1993, Blood.

[24]  J. Michaeli,et al.  Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. , 1992, Blood.

[25]  R. Ohno,et al.  An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Oscier.  Myelodysplastic syndromes. , 2007, Bailliere's clinical haematology.

[27]  B. Cheson,et al.  Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. , 1987, Seminars in oncology.

[28]  D. Machin,et al.  Myelodysplastic syndromes: a scoring system with prognostic significance , 1985, British journal of haematology.